The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

Auteurs

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J

  • Date de publication

    Juni 2025

  • Type

    Article

  • Tijdschrift

    ESMO Open

  • Naam van de onderzoeker

    PICCART MARTINE

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Médecine Oncologique

  • PMID

    40460679

  • DOI

    10.1016/j.esmoop.2025.105294